Search
Search Results
##search.searchResults.foundPlural##
-
IMMUNOLOGICAL EVOLUTION OF A COHORT OF HIV-2 INFECTED PATIENTS: PECULIARITIES OF AN UNDERESTIMATED INFECTION HIV-2 INFECTED PATIENTS PECULIARITIES
1015PDF: 637HTML: 237 -
CAR-T CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA CAR-T and CLL
3759PDF: 1643HTML: 83 -
REAL-WORLD OUTCOME IN THE PRE-CAR-T ERA OF MYELOMA PATIENTS QUALIFYING FOR CAR-T CELL THERAPY Real-world Assessment of Myeloma Patients as Candidates for CAR-T Therapy
1624PDF: 644HTML: 550 -
How I treat acute and persistent sickle cell pain
2012PDF: 1132HTML: 495 -
-
PEDIATRIC MASTOCYTOSIS: AN UPDATE Chldren' Mastocytosis
1905HTML: 1504PDF: 1125 -
THE SPECTRUM OF GENETIC DEFECTS IN CHRONIC LYMPHOCYTIC LEUKEMIA
2301PDF: 902HTML: 2010Fig 1 Rossi: 204 -
CHRONIC MYELOGENOUS LEUKEMIA (CML) IN THE ELDERLY
2920PDF: 1127HTML: 3039 -
miR-155-5p PROMOTES CD34+ APOPTOSIS AND INHIBITS BONE MARROW HEMATOPOIESIS IN MYELODYSPLASTIC SYNDROMES BY RAC1/CREB/MIR-15B AXIS
769PDF: 892PDF Supp. Files: 81HTML: 196 -
THE PROTHROMBOTIC STATE ASSOCIATED WITH SARS-COV-2 INFECTION: PATHOPHYSIOLOGICAL ASPECTS COVID and Thrombosis
2036PDF: 827HTML: 229 -
AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR HIGH-RISK ACUTE LYMPHOBLASTIC LEUKEMIA: NON-RANDOMIZED STUDY WITH A MAXIMUM FOLLOW-UP OF MORE THAN 22 YEARS
1576PDF: 926HTML: 1969Figure: 183Tables: 195ALL revision 1: 269response to reviewer: 189 -
ARA-C, IDARUBICINE AND GENTUZUMAB OZOGAMICIN (AIM) AS SALVAGE TREATMENT IN ADVANCED ACUTE MYELOID LEUKEMIA PATIENTS
1717PDF: 832HTML: 940cover letter: 284 -
RECENT ADVANCES IN THE DEFINITION OF THE MOLECULAR ALTERATIONS OCCURRING IN MULTIPLE MYELOMA MOLECULAR ALTERATIONS OCCURRING IN MM
1286PDF: 1087HTML: 219 -
CAR-T CELL THERAPY FOR FOLLICULAR LYMPHOMAS CAR-T and Follicular Lymphoma
2409PDF: 1876HTML: 154 -
NPM1 MUTATED, BCR-ABL1 POSITIVE MYELOID NEOPLASMS: REVIEW OF LITERATURE NPM1 mutated, BCR-ABL1 positive myeloid neoplasms
1755PDF: 1213HTML: 243 -
ENDOTHELIAL BIOMARKERS IN PATIENTS RECOVERED FROM COVID-19 ONE YEAR AFTER HOSPITAL DISCHARGE: A CROSS-SECTIONAL STUDY Endothelial biomarkers in COVID-19 recoverers one year after hospital discharge.
1342PDF: 750HTML: 333 -
SUSTAINED REMISSION IN AN ELDERLY PATIENT WITH ACUTE MYELOID LEUKEMIA FOLLOWING GILTERITINIB TREATMENT AS THIRD-LINE SALVAGE THERAPY Long-lasting disease remission with third line therapy with gilteritinib
966PDF: 527HTML: 217 -
CHRONIC MYELOPROLIFERATIVE NEOPLASMS: A COLLABORATIVE APPROACH
1729PDF: 751HTML: 2347 -
WALDENSTROM’S MACROGLOBULINEMIA: AN UPDATE
7742PDF: 2455HTML: 1745Table 1.: 227Table 2.: 239Table 3.: 222Table 4.: 216 -
CAR-T CELL THERAPY FOR T-CELL MALIGNANCIES CAR-T CELL FOR T-CELL MALIGNANCIES
2239PDF: 2073HTML: 202 -
ACQUIRED REFRACTORY IRON DEFICIENCY
3493PDF: 1220HTML: 1147 -
MONITORING THE RESPONSE TO TYROSINE KINASE INHIBITOR (TKI) TREATMENT IN CHRONIC MYELOID LEUKEMIA (CML)
4063PDF: 1561HTML: 9194Untitled: 287Untitled: 194Untitled: 179Untitled: 172Untitled: 196Untitled: 352 -
LYMPHOCYTES IN PATIENTS WITH CHRONIC ACTIVE EPSTEIN-BARR VIRUS INFECTION EXHIBITED ELEVATED PD-1/PD-L1 EXPRESSION AND A PREVAILING TH2 IMMUNE RESPONSE. EPSTEIN-BARR VIRUS INFECTION EXHIBITED ELEVATED PD-1/PD-L1
2879PDF: 1114HTML: 126 -
COMPARISON OF INFECTIOUS COMPLICATIONS IN PATIENTS RECEIVING HIGH-DOSE CYCLOPHOSPHAMIDE AS GVHD AFTER TRANSPLANTATION FROM A 9/10 HLA-MATCHED UNRELATED DONOR WITH STANDARD GVHD PROPHYLAXIS AFTER TRANSPLANT FROM A FULL MATCHING DONOR Infection With PTCy Versus Standard GvHD Prophylaxis
1460PDF: 1344HTML: 109







